十一酸睾酮联合血府逐瘀口服液治疗少弱精子症的临床研究

摘要

目的：观察十一酸睾酮联合血府逐瘀口服液治疗少、弱精子症患者的疗效。方法：采用随机对照的临床研究，将确诊的150例患者随机分为对照组（70例）和治疗组（80例）。对照组服用 VitE，100mg／次，2次／d；治疗组服用十一酸睾酮胶丸治疗，每次40mg，2次／d，同时联合血府逐瘀口服液，每次10mL，3次／d。两组治疗3月后，分别检测精液质量（精液量、精子浓度、前向运动精子、精子 DFI）及妊娠率。结果：有140例患者完成了临床研究，治疗组在精液量、精子浓度、前向运动精子、精子 DFI 方面较用药前均有显著的改善（P ＜0.05），并在改善精子浓度、前向运动精子、精子 DFI 及妊娠率方面，疗效优于对照组（P ＜0.05）。结论：十一酸睾酮联合血府逐瘀口服液可显著改善少、弱精子症患者的精子质量和妊娠率，可以作为临床治疗男性不育症的安全有效方案。%Objectives:To observe the efficacy of testosterone undecanoate and Xuefu Zhuyu oral liquid in the treatment of oligoasthenospermia.Methods:In the randomized controlled study,150 diagnosed infertile men with oligoasthenospermia were divided into two groups including the control group (70 cases)and the treatment group (80 cases).The control group received VitE,100mg once,bid.The treatment group was given testosterone undecanoate,40mg,bid,with Xuefu Zhuyu oral liquid,10 ml,tid.After the treatment of 3 months,the semen volume,spermatozoa density,prorsad spermatozoa rate,spermatozoa DFI,and pregnancy rate of the two groups were compared.Results:A total of 140 patients accomplished the clinical trial.In the treatment group,the index of semen volume,spermatozoa density,prorsad spermatozoa rate,spermatozoa DFI,were obviously improved com-pared to pre -treatment (P <0.05).Besides,it was obviously ameliorated of spermatozoa density,prorsad sperma-tozoa rate,spermatozoa DFI,and pregnancy rate compared to the control group (P <0.05).Conclusion:Testos-terone undecanoate and Xuefu Zhuyu oral liquid can evidently improve the seminal quality and pregnancy rate of oli-goasthenospermia patients,which can serve as a safe and effective clinical treatment method for male infertility pro-gram.